Review





Similar Products

chicken major histocompatibility complex class ii expressing antigen presenting cells  (Thermo Fisher)
90
Thermo Fisher chicken major histocompatibility complex class ii expressing antigen presenting cells
Chicken Major Histocompatibility Complex Class Ii Expressing Antigen Presenting Cells, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chicken major histocompatibility complex class ii expressing antigen presenting cells/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
chicken major histocompatibility complex class ii expressing antigen presenting cells - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
human hla dra recombinant protein  (Cusabio)
92
Cusabio human hla dra recombinant protein
Human Hla Dra Recombinant Protein, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human hla dra recombinant protein/product/Cusabio
Average 92 stars, based on 1 article reviews
human hla dra recombinant protein - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier
human hla-dqb2 (hla class ii histocompatibility antigen, dq beta 2 chain) (eh9135)  (Wuhan Fine Biotech)
90
Wuhan Fine Biotech human hla-dqb2 (hla class ii histocompatibility antigen, dq beta 2 chain) (eh9135)
Human Hla Dqb2 (Hla Class Ii Histocompatibility Antigen, Dq Beta 2 Chain) (Eh9135), supplied by Wuhan Fine Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human hla-dqb2 (hla class ii histocompatibility antigen, dq beta 2 chain) (eh9135)/product/Wuhan Fine Biotech
Average 90 stars, based on 1 article reviews
human hla-dqb2 (hla class ii histocompatibility antigen, dq beta 2 chain) (eh9135) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
hla class ii histocompatibility antigen antibodies  (Agilent technologies)
90
Agilent technologies hla class ii histocompatibility antigen antibodies
Hla Class Ii Histocompatibility Antigen Antibodies, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hla class ii histocompatibility antigen antibodies/product/Agilent technologies
Average 90 stars, based on 1 article reviews
hla class ii histocompatibility antigen antibodies - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
hla class ii histocompatibility antigen dr alpha chain  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc hla class ii histocompatibility antigen dr alpha chain
Hla Class Ii Histocompatibility Antigen Dr Alpha Chain, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hla class ii histocompatibility antigen dr alpha chain/product/Cell Signaling Technology Inc
Average 95 stars, based on 1 article reviews
hla class ii histocompatibility antigen dr alpha chain - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
major histocompatibility class ii antigen (mhc-ii) pe  (ImmunoTools)
90
ImmunoTools major histocompatibility class ii antigen (mhc-ii) pe
Major Histocompatibility Class Ii Antigen (Mhc Ii) Pe, supplied by ImmunoTools, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/major histocompatibility class ii antigen (mhc-ii) pe/product/ImmunoTools
Average 90 stars, based on 1 article reviews
major histocompatibility class ii antigen (mhc-ii) pe - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
human hla class ii histocompatibility antigen, dr alpha chain (hla-dra) elisa kit  (Cusabio)
90
Cusabio human hla class ii histocompatibility antigen, dr alpha chain (hla-dra) elisa kit
Quantification of sHLA class I molecules in COVID-19 patients, SARS-CoV-2 convalescent individuals and healthy donors (A) Soluble HLA class I levels in the serum of COVID-19 (n = 31), Convalescent (n = 290) and Control donors (n = 80). See <xref ref-type=Figure S3 A for sHLA-DR. (B and C) Longitudinal follow-up analysis of sHLA class I levels in (B) convalescent individuals (n = 53) at different timepoints ( T1 , timepoint 1, 19 - 52 days after positive PCR; T2 , timepoint 2, 141 - 170 days after positive PCR) and (C) compared to healthy control donors ( Control , n = 80). (D) Soluble HLA class I levels in the serum of convalescents with ( persisting symptoms , n = 51) and without ( asymptomatic , n = 11) persistence of symptoms after SARS-CoV-2 infection compared to healthy control donors ( Control , n = 80). (E) Soluble HLA class I serum levels in COVID-19 patients with (n = 4) and without (n = 26) requirement for invasive ventilation. (F) Correlation analysis of sHLA class I levels to SARS-CoV-2-specific T cell response intensities in terms of calculated spot counts in ELISpot assays in convalescent individuals (n = 68). Linear regression line with 95% confidence level (dotted lines), Spearman’s rho (ρ) and p value. Each dot represents the sHLA class I serum level of one donor measured by enzyme-linked immunosorbent assay (ELISA). Boxes represent median and 25 th to 75 th percentiles, whiskers are minimum to maximum. Different symbols represent COVID-19-specific treatment (no treatment, remdesivir, dexamethasone, combined treatment with remdesivir and dexamethasone) for the COVID-19 cohort within three days before sample collection. (A, D) Kruskal-Wallis test, (B) Wilcoxon matched-pairs signed rank test, (C) Mann-Whitney U test comparing T1 or T2 to Control . " width="250" height="auto" />
Human Hla Class Ii Histocompatibility Antigen, Dr Alpha Chain (Hla Dra) Elisa Kit, supplied by Cusabio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human hla class ii histocompatibility antigen, dr alpha chain (hla-dra) elisa kit/product/Cusabio
Average 90 stars, based on 1 article reviews
human hla class ii histocompatibility antigen, dr alpha chain (hla-dra) elisa kit - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
human hla class ii histocompatibility antigen  (Cusabio)
93
Cusabio human hla class ii histocompatibility antigen
Quantification of sHLA class I molecules in COVID-19 patients, SARS-CoV-2 convalescent individuals and healthy donors (A) Soluble HLA class I levels in the serum of COVID-19 (n = 31), Convalescent (n = 290) and Control donors (n = 80). See <xref ref-type=Figure S3 A for sHLA-DR. (B and C) Longitudinal follow-up analysis of sHLA class I levels in (B) convalescent individuals (n = 53) at different timepoints ( T1 , timepoint 1, 19 - 52 days after positive PCR; T2 , timepoint 2, 141 - 170 days after positive PCR) and (C) compared to healthy control donors ( Control , n = 80). (D) Soluble HLA class I levels in the serum of convalescents with ( persisting symptoms , n = 51) and without ( asymptomatic , n = 11) persistence of symptoms after SARS-CoV-2 infection compared to healthy control donors ( Control , n = 80). (E) Soluble HLA class I serum levels in COVID-19 patients with (n = 4) and without (n = 26) requirement for invasive ventilation. (F) Correlation analysis of sHLA class I levels to SARS-CoV-2-specific T cell response intensities in terms of calculated spot counts in ELISpot assays in convalescent individuals (n = 68). Linear regression line with 95% confidence level (dotted lines), Spearman’s rho (ρ) and p value. Each dot represents the sHLA class I serum level of one donor measured by enzyme-linked immunosorbent assay (ELISA). Boxes represent median and 25 th to 75 th percentiles, whiskers are minimum to maximum. Different symbols represent COVID-19-specific treatment (no treatment, remdesivir, dexamethasone, combined treatment with remdesivir and dexamethasone) for the COVID-19 cohort within three days before sample collection. (A, D) Kruskal-Wallis test, (B) Wilcoxon matched-pairs signed rank test, (C) Mann-Whitney U test comparing T1 or T2 to Control . " width="250" height="auto" />
Human Hla Class Ii Histocompatibility Antigen, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human hla class ii histocompatibility antigen/product/Cusabio
Average 93 stars, based on 1 article reviews
human hla class ii histocompatibility antigen - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


Quantification of sHLA class I molecules in COVID-19 patients, SARS-CoV-2 convalescent individuals and healthy donors (A) Soluble HLA class I levels in the serum of COVID-19 (n = 31), Convalescent (n = 290) and Control donors (n = 80). See <xref ref-type=Figure S3 A for sHLA-DR. (B and C) Longitudinal follow-up analysis of sHLA class I levels in (B) convalescent individuals (n = 53) at different timepoints ( T1 , timepoint 1, 19 - 52 days after positive PCR; T2 , timepoint 2, 141 - 170 days after positive PCR) and (C) compared to healthy control donors ( Control , n = 80). (D) Soluble HLA class I levels in the serum of convalescents with ( persisting symptoms , n = 51) and without ( asymptomatic , n = 11) persistence of symptoms after SARS-CoV-2 infection compared to healthy control donors ( Control , n = 80). (E) Soluble HLA class I serum levels in COVID-19 patients with (n = 4) and without (n = 26) requirement for invasive ventilation. (F) Correlation analysis of sHLA class I levels to SARS-CoV-2-specific T cell response intensities in terms of calculated spot counts in ELISpot assays in convalescent individuals (n = 68). Linear regression line with 95% confidence level (dotted lines), Spearman’s rho (ρ) and p value. Each dot represents the sHLA class I serum level of one donor measured by enzyme-linked immunosorbent assay (ELISA). Boxes represent median and 25 th to 75 th percentiles, whiskers are minimum to maximum. Different symbols represent COVID-19-specific treatment (no treatment, remdesivir, dexamethasone, combined treatment with remdesivir and dexamethasone) for the COVID-19 cohort within three days before sample collection. (A, D) Kruskal-Wallis test, (B) Wilcoxon matched-pairs signed rank test, (C) Mann-Whitney U test comparing T1 or T2 to Control . " width="100%" height="100%">

Journal: iScience

Article Title: Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity

doi: 10.1016/j.isci.2022.105643

Figure Lengend Snippet: Quantification of sHLA class I molecules in COVID-19 patients, SARS-CoV-2 convalescent individuals and healthy donors (A) Soluble HLA class I levels in the serum of COVID-19 (n = 31), Convalescent (n = 290) and Control donors (n = 80). See Figure S3 A for sHLA-DR. (B and C) Longitudinal follow-up analysis of sHLA class I levels in (B) convalescent individuals (n = 53) at different timepoints ( T1 , timepoint 1, 19 - 52 days after positive PCR; T2 , timepoint 2, 141 - 170 days after positive PCR) and (C) compared to healthy control donors ( Control , n = 80). (D) Soluble HLA class I levels in the serum of convalescents with ( persisting symptoms , n = 51) and without ( asymptomatic , n = 11) persistence of symptoms after SARS-CoV-2 infection compared to healthy control donors ( Control , n = 80). (E) Soluble HLA class I serum levels in COVID-19 patients with (n = 4) and without (n = 26) requirement for invasive ventilation. (F) Correlation analysis of sHLA class I levels to SARS-CoV-2-specific T cell response intensities in terms of calculated spot counts in ELISpot assays in convalescent individuals (n = 68). Linear regression line with 95% confidence level (dotted lines), Spearman’s rho (ρ) and p value. Each dot represents the sHLA class I serum level of one donor measured by enzyme-linked immunosorbent assay (ELISA). Boxes represent median and 25 th to 75 th percentiles, whiskers are minimum to maximum. Different symbols represent COVID-19-specific treatment (no treatment, remdesivir, dexamethasone, combined treatment with remdesivir and dexamethasone) for the COVID-19 cohort within three days before sample collection. (A, D) Kruskal-Wallis test, (B) Wilcoxon matched-pairs signed rank test, (C) Mann-Whitney U test comparing T1 or T2 to Control .

Article Snippet: Human HLA Class II Histocompatibility Antigen, DR Alpha Chain (HLA-DRA) ELISA kit , Cusabio , Cat# CSB-EL010497HU.

Techniques: Control, Infection, Enzyme-linked Immunospot, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY

Journal: iScience

Article Title: Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity

doi: 10.1016/j.isci.2022.105643

Figure Lengend Snippet:

Article Snippet: Human HLA Class II Histocompatibility Antigen, DR Alpha Chain (HLA-DRA) ELISA kit , Cusabio , Cat# CSB-EL010497HU.

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Protease Inhibitor, Mass Spectrometry, Generated, Software